It has been more than 35 years since the lung was discovered to be lined with a layer of surface-active material that is important in lung stability and mechanics of respiration. 1-4 The absence of this "anti-atelectasis" factor2,3 was proposed by Avery and Mead in 1959 to be the cause of hyaline membrane disease of premature infants.5 An indepth historical review of pulmonary surfactant by Tierney 6 was recently published. In the years since 1959, there has been an exhaustive amount of research aimed at elucidating the structure and function of pulmonary surfactant, the ultimate goal being a safe and effective exogenous surfactant for the treatment of the Respiratory Distress Syndrome (RDS). The days of surfactant research are far from over, but the era of surfactant replacement therapy is now upon us. The practitioner needs to be knowledgeable about surfactant and aware of his or her role in surfactant therapy for premature infants. The following is intended to clarify some of the important issues of surfactant replacement.
Get full access to this article
View all access options for this article.
References
1.
Radford EP, Jr. Method for estimating respiratory surface area of mammalian lungs from their physical characteristics. Proc Soc Exp Biol Med1954; 87:58-61.
Clements JA, Brown ES, Johnson RPPulmonary surface tension and the mucous lining of the lungs: some theoretical considerations. J Appl Physiol1958; 12:262-8.
4.
Pattle REProperties function, and origin of the alveolar lining layer. Nature (Lond)1955; 175:1125-6.
5.
Avery ME, Mead J.Surface properties in relation to atelectasis and hyaline membrane disease . AJDC1959; 97:517-523.
6.
Tierney DFLung surfactant: some historical perspectives leading to its cellular and molecular biology. Am J Physiol1989; 275:L1-L12.
7.
Jobe A.Surfactant and the developing lung. In: Neonatal Pulmonary Care. edited by DW Thibeault and GA Gregory.Addison-Wesley.
8.
Gluck L., Kulovich MV, Borer RC Jr, et al. The interpretation and significance of the lecithin/sphingomyelin ratio in amniotic fluid. Am J Obstet Gynecol1974; 120:142-155.
9.
Hallman M., Feldman BH, Kirkpatrich E., et al. Absence of phosphatidylgycerol (PG) in respiratory distress syndrome in the newborn. Pediatr Res1977; 11:714-20.
10.
Kulovich MV , Hallman MB, Gluck L.The lung profile I: Normal pregnancy. Am J Obstet Gynecol1979; 135:57-63.
11.
Beppu OS, Clements JA, Goerke J.Phosphatidylglycerol-deficient lung surfactant has normal properties. J Appl Physiol1983; 55:496-502.
12.
King RJ, Klass DJ, Gikas EG, et al. Isolation of apoproteins from canine surface active material . Am J Physiol1973; 224:788-93.
13.
Hawgood S., Benson BJ, Hamilton RLEffects of a surfactant-associated protein and calcium ions on the structure and surface activity of lung surfactant lipids. Biochemistry1985; 24:184-190.
14.
King RJ, Simon D., Horowitz M.Aspects of secondary and quaternary structure of surfactant protein A from canine lung. Biochim Biophys Acta1989; 1001: 294-301.
15.
Haagsman HP , White RT, Schilling J., et al. Studies of the structure of lung surfactant protein SP-A. Am J Physiol1989; 257:L421-L9.
16.
Whitsett JA , Hull WM, Ohning B., et al. Hydrophobic surfactant-associated protein in whole lung surfactant and its importance for biophysical activity in lung surfactant extracts used in replacement therapy. Pediatr Res1986; 20:460-7.
17.
Yu S-H. , Possmayer F.Reconstitution of surfactant activity by using the 6kDa apoprotein associated with pulmonary surfactant. Biochem J1986; 236:85-9.
18.
Enhorning G. , Hill D., Sherwood G., et al. Improved ventilation of prematurely derived primates following tracheal deposition of surfactant. Am J Obstet Gynecol1978; 132:529-36.
19.
Ikegami M., Jobe A., Jacobs H., et al. Sequential treatments of premature lambs with an artificial surfactant and natural surfactant. J Clin Invest1981; 68:491-6.
20.
Jobe A., Ikegami M., Glatz T., et al. Duration and characteristics of treatment of premature lambs with natural surfactant. J Clin Invest1981 ; 67:370-5.
21.
Jobe A., Ikegami M.The prematurely delivered lamb as a model for studies of neonatal adaptation . In: Animal Models in Fetal Medicine, edited by PW Nathanielsz.Perinatal Press, 1984, p.8.
22.
Fujiwara T.Surfactant replacement in neonatal RDS. In Robertson B, van Golde LMG, Bratenburg JJ (eds). Pulmonary surfactant. Amsterdam, The Netherlands, Elsevier, 1984, pp479-504.
23.
Egan EA, Notter Rh, Kwong MS, et al. Natural and artificial surfactant replacement in premature lambs . J Appl Physiol1983; 55:875-83.
24.
Collaborative European Multicenter Study Group. Surfactant replacement therapy in severe neonatal respiratory distress syndrome; an international randomized clinical trial. Pediatr1988; 82:683-91.
25.
Hallman M., Merritt TA, Jarvenpaa AL, et al. Exogenous human surfactant for treatment of severe respiratory distress syndrome. J Pediatr1985; 106:963- 9.
26.
Merritt TA, Hallman M., Bloom BT, et al. Prophylactic treatment of very premature infants with human surfactant. N Engl J Med1986; 315:785-90.
27.
Robillard E. , Alarie Y., Dagenais-Perusse P., et al. Microaerosol administration of synthetic dipalmitoyl lecithin in the respiratory distress syndrome: a preliminary report. Can Med Assoc J1964; 90:55-7.
28.
Chu J., Clements JA, Cotton EK, et al. Neonatal pulmonary ischemia: clinical and physiological studies . Pediatr1967; 40:709-82.
29.
Morley CJ, Bangham AD, Miller N., et al. Dry artificial lung surfactant and its effect on very premature babies. Lancet1981; 1:64-8.
30.
Ikegami M., Jobe A., Jacobs H., et al. Testing an artificial surfactant in premature lambs. Pediatr Res1981;15:665A.
31.
Durand DJ, Clyman RI, Heymann MA, et al. Effects of a protein-free synthetic surfactant on survival and pulmonary function in preterm lambs. J Pediatr1985; 107:775-80.
32.
Jobe A., Ikegami M., Jacobs H., et al. Surfactant and pulmonary blood flow distributions following treatment of premature lambs with natural surfactant. J Clin Invest1984; 73:848-50.
33.
Nilsson R., Grossmann G., Robertson B.Lung surfactant and the pathogenesis of neonatal bronchiolar lesions induced by artifical ventilation. Pediatr Res1978 ; 12:249-55.
34.
Robertson B. , Berry D., Curstedt T., et al. Leakage of protein in the immature rabbit lung; effect of surfactant replacement. Resp Physiol1985; 61:265-76.
35.
Jobe A., Jacobs H., Ikegami M., et al. Lung protein leaks in ventilated lambs: effect of gestational age. J Appl Physiol1985; 58:1246-52.
36.
Ikegami M., Jobe A., Jacobs H., et al. A protein from airways of premature lambs that inhibits surfactant function. J Appl Physiol1984; 57:1134-42.
37.
Ikegami M., Jobe A., Berry D.A protein that inhibits surfactant function in respiratory distress syndrome . Biol Neonate1986; 50:121-9.
38.
Gitlin JD, Soll RD, Parad RB, et al. Randomized control trial of exogenous surfactant for the treatment of hyaline membrane disease. Pediatr1987; 79:31-7.
39.
Raju TN, Vidyasagar D., Bhat R., et al. Double-blind controlled trial of single-dose treatment with bovine surfactant in severe hyaline membrane disease. Lancet1987; 1:651-6.
40.
Fujiwara T. , Konishi M., Chida S., et al. Surfactant replacement therapy with a single postventilatory dose of a reconstituted bovine surfactant in preterm neonates with respiratory distress syndrome: Final analysis of a multicenter, double-blind randomized trial and comparison with similar trials. Pediatr1990; 86:753-64.
41.
Horbar JD, Soll RF, Schachinger H., et al. A European multicenter randomized controlled trial of single dose surfactant therapy for idiopathic respiratory distress syndrome. EurJ Pediatr1990; 149:416-23.
42.
Canadian Exosurf Pediatric Study Group.Effects of two rescue doses of Exosurf Pediatric® in 342 750-1249 gram infants . Pediatr Res1990; 27:200A.
43.
Long W., Thompson T., Sundell H., et al. Two rescue doses of a synthetic surfactant in 700-1350 gram infants with RDS reduce overall mortality by one half. J Pediatr (in press).
44.
Enhoming G. , Shennan A., Possmayer F., et al. Prevention of neonatal respiratory distress syndrome by tracheal instillation of surfactant: a randomized clinical trial. Pediatr1985; 76:145-53.
45.
Kwong MS, Egan EA, Notter RH, et al. Double-blind clinical trial of calf lung surfactant extract for the prevention of hyaline membrane disease in extremely premature infants . Pediatr1985; 76: 585-92.
46.
Soll RF, Hoekstra RE, Fangman JJ, et al. Multicenter trial of single dose modified bovine surfactant extract (Survanta) for prevention of respiratory distress syndrome. Pediatr1990; 85:1092-1102.
47.
Corbet A., Bucciarelli R., Goldman S., et al. Decreased mortality in small premature infants treated at birth with a single dose of synthetic surfactant: A multicenter controlled trial . J Pediatr (in press).
48.
Bose C., Corbet A., Bose G., et al. Improved outcome at 28 days of age for very low birth weight infants treated with a single dose of a synthetic surfactant. J Pediatr1990; 117:947-53.
49.
Clark DA, Nieman GF, Thompson JE, et al. Surfactant displacement by meconium free fatty acids: an alternative explanation for atelectasis in meconium aspiration syndrome. J Pediatr1987; 110:765-70.
50.
Berry DD, Block SMSurfactant inhibition following meconium aspiration in rabbits. Pediatr Res1990; 27:296A.
51.
Berry D., Ikegami M., Jobe A.Respiratory distress and surfactant inhibition following vagotomy in rabbits . J Appl Physiol1986; 61:1741-48.
52.
Notter RH, Shapiro DLLung surfactants for replacement therapy: biochemical, biophysical and clinical aspects. Clin Perinatol1987; 14:433-79.
